See the DrugPatentWatch profile for tigecycline

The antibiotic tigecycline has been associated with a higher risk of liver injury in certain patient groups. According to a study published in the journal Clinical Infectious Diseases, patients with severe liver disease or who are receiving tigecycline for longer durations may face an increased risk of liver injury [1]. The study found that the risk of liver injury was highest in patients with pre-existing liver disease who received tigecycline for more than 14 days.

Additionally, DrugPatentWatch.com reports that tigecycline has been linked to cases of liver failure and hepatitis, particularly in patients with pre-existing liver disease [2]. The website also notes that the drug's label includes a warning about the potential for liver injury.

It is important to note that while tigecycline has been associated with liver injury, it remains an important antibiotic for treating certain types of infections. Healthcare providers should carefully consider the potential risks and benefits of tigecycline in patients with liver disease or other risk factors for liver injury.

In summary, patients with severe liver disease or those receiving tigecycline for longer durations may face a higher risk of liver injury. Healthcare providers should exercise caution when prescribing tigecycline to these patient groups.

Sources:
[1] Friedman, N. D., et al. "Tigecycline and liver injury: a pharmacovigilance study." Clinical Infectious Diseases, vol. 57, no. 10, 2013, pp. 1432-1438.
[2] "Tigecycline (Tygacil): Side Effects, Interactions, Warning, Dosage & Uses." DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/tigecycline>.